Why the study?
The specific role of cardiomyocyte CXCR4 in heart function and the pathogenesis of heart failure was incompletely understood.
Does cardiomyocyte-specific CXCR4 ablation exacerbate isoproterenol-induced cardiac dysfunction and remodeling?
Does cardiomyocyte-specific CXCR4 ablation exacerbate isoproterenol-induced cardiac dysfunction and remodeling?
Cardiomyocyte SDF-1/CXCR4 signaling alleviates beta-adrenergic stress-induced cell death and adverse cardiac remodeling, suggesting a potential therapeutic target for heart failure.
CXCR4 in cardiomyocytes may protect against β-adrenergic stress; animal data leave open its role in human heart failure.
Heart failure is an ageing-associated disease. CXCR4, a seven-transmembrane-spanning Gi-coupled receptor for the SDF-1 chemokine, plays a critical role in organogenesis, healthy ageing, vascular post-injury repair and regeneration; however, the specific role of cardiomyocyte CXCR4 in heart function and the pathogenesis of heart failure is incompletely understood. We hypothesize that CXCR4 expression in cardiomyocytes is protective during β-adrenoceptor/Gs stress-induced cardiac dysfunction. Cardiomyocyte-specific CXCR4 knockout (CXCR4- CM KO) mice were generated by crossing CXCR4 fl/fl and MHC-Cre +/− mice and shown to display normal cardiac structure and function in the basal state until at least 4 months old. However, following continuous administration of isoproterenol (Iso) via an osmotic mini-pump, their ventricular myocardial contractility, dilation, cardiomyocyte apoptosis, and interstitial fibrosis were worsened compared to that of control MHC-Cre +/− littermates under same treatment. In the cultured H9C2 cardiomyocytes, SDF-1 treatment markedly attenuated Iso-induced apoptosis and reduction in phospho-Akt, and these protective effects were diminished by knockdown of CXCR4 or by co-treatment with Gi inhibitors. Thus, cardiomyocyte SDF-1/CXCR4 signaling alleviates β-adrenergic stress-induced cell death and cardiac adverse remodeling, thus may be harnessed for treatment of heart failure.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: